- Home
- JLL vs BBIO Comparison
JLL vs BBIO Comparison
Compare JLL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLL | BBIO |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 14.7B |
| IPO Year | 1997 | 2019 |
Fundamental Metrics
Financial Performance| Metric | JLL | BBIO |
|---|---|---|
| Price | $340.99 | $75.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 21 |
| Target Price | ★ $342.14 | $76.24 |
| AVG Volume (30 Days) | 325.6K | ★ 1.8M |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.91 | N/A |
| EPS | ★ 13.05 | N/A |
| Revenue | ★ $25,317,800,000.00 | $353,780,000.00 |
| Revenue This Year | $11.62 | $127.64 |
| Revenue Next Year | $7.13 | $78.38 |
| P/E Ratio | $26.59 | ★ N/A |
| Revenue Growth | 12.51 | ★ 62.46 |
| 52 Week Low | $194.36 | $27.23 |
| 52 Week High | $347.52 | $78.44 |
Technical Indicators
Market Signals| Indicator | JLL | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 61.47 | 60.10 |
| Support Level | $330.62 | $75.82 |
| Resistance Level | $347.52 | $77.48 |
| Average True Range (ATR) | 7.95 | 2.20 |
| MACD | 0.42 | -0.34 |
| Stochastic Oscillator | 78.27 | 61.00 |
Price Performance
Historical ComparisonAbout JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.